| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-115-9-700 |
| P698 | PubMed publication ID | 1656828 |
| P2093 | author name string | A. M. Di Bisceglie | |
| J. H. Hoofnagle | |||
| M. Shindo | |||
| S. M. Feinstone | |||
| J. W. Shih | |||
| L. Cheung | |||
| K. Cristiano | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic hepatitis | Q62019625 |
| hepatitis C | Q154869 | ||
| internal medicine | Q11180 | ||
| P304 | page(s) | 700-704 | |
| P577 | publication date | 1991-11-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C | |
| P478 | volume | 115 |
| Q43037205 | "Rebound" phenomenon of hepatitis C viremia after interferon therapy in "relapsed" patients with chronic hepatitis C. |
| Q43000230 | A comparison between the phenol-chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum |
| Q28318414 | A pilot study of ribavirin therapy for chronic hepatitis C |
| Q42992074 | A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. |
| Q43041046 | A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. |
| Q42977220 | Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study |
| Q43048243 | Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major |
| Q43498442 | Analytical and laboratory evaluation of a new fully-automated third generation enzyme immunoassay for the detection of antibodies to the hepatitis C virus |
| Q27477787 | Antibody production against hepatitis C virus core and nonstructural 3 proteins is highly sensitive to deficits in T-cell function |
| Q57662881 | Antibody-fused interferons as an effective approach to enhance target specificity and antiviral efficacy of type I interferons |
| Q40915885 | Antiviral therapy of hepatitis C--present and future |
| Q36070394 | Antiviral therapy: current concepts and practices |
| Q72898835 | Autoimmunity during alpha-interferon therapy for chronic hepatitis C |
| Q33432442 | Beta interferon therapy for chronic hepatitis C in patients with haemophilia and other haemorrhagic disorders |
| Q43039294 | Changes in hepatitis C virus antigen in liver with antiviral therapy |
| Q43041363 | Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C. |
| Q42998874 | Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2b |
| Q43036067 | Characterization of the 5′ noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment |
| Q35337473 | Chronic hepatitis B and C. What is the status of drug therapy? |
| Q43048302 | Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis |
| Q40391241 | Clinical immunology and infectious diseases. |
| Q43035669 | Clinical significance of hepatitis C virus (HCV) infection in liver transplant recipients. Role of serology and HCV RNA detection. |
| Q35233963 | Clinical spectrum of viral infections in hemophilic patients |
| Q42977731 | Cold activation of complement in sera from patients with persistent hepatitis C virus infection on interferon therapy |
| Q45297184 | Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial† |
| Q43034948 | Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viraemia and histologic activity |
| Q27485763 | Comparison of a competitive combined reverse transcription-PCR assay with a branched-DNA assay for hepatitis C virus RNA quantitation |
| Q43041441 | Comparison of quantitative cDNA-PCR with the branched DNA hybridization assay for monitoring plasma hepatitis C virus RNA levels in haemophilia patients participating in a controlled interferon trial |
| Q42993471 | Comparison of the enzyme-linked immunosorbant assay III, recombinant immunoblot third generation assay, and polymerase chain reaction method in the detection of hepatitis C virus infection in haemodialysis patients |
| Q43038340 | Cryoglobulinemia: a cause for false negative polymerase chain reaction results in patients with hepatitis C virus positive chronic liver disease |
| Q27485648 | Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: comparison with nested amplification and antibody testing |
| Q27478427 | Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon |
| Q27487585 | Detection of hepatitis C virus RNA: comparison of one-stage polymerase chain reaction (PCR) with nested-set PCR |
| Q72131883 | Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon |
| Q42987367 | Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C |
| Q45886653 | Effect and side-effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C. |
| Q43038795 | Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients |
| Q34210742 | Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma |
| Q43871989 | Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. |
| Q33809548 | Effects of interferon therapy in "non responder" patients with chronic hepatitis C. |
| Q43048309 | Effects of interferon-alpha on serum hepatitis C virus in patients with chronic hepatitis C. |
| Q42631714 | Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection |
| Q27473016 | Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA |
| Q45783488 | Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis |
| Q27486399 | Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals |
| Q42999502 | Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. |
| Q43035052 | Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. |
| Q21245273 | Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials |
| Q73824104 | Fulminant hepatitis in patients undergoing liver transplantation: Evidence for a non-A, non-B, non-C, non-D, and non-E syndrome |
| Q43035819 | Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. |
| Q43041871 | Genotypic analysis of hepatitis C virus in American patients |
| Q50587870 | Glomerulonephritis associated with hepatitis c virus infection |
| Q43048108 | HCV RNA in patients with chronic hepatitis C treated with interferon-alpha |
| Q42983650 | HCV genotypes in patients with liver disease of different stages and severity |
| Q42982244 | HCV infection in symptom-free patients |
| Q43037715 | HCV replication in mononuclear cells stimulates anti‐HCV‐secreting B cells and reflects nonresponsiveness to interferon‐α |
| Q60023612 | HLA class II favors clearance of HCV infection and progression of the chronic liver damage |
| Q33929132 | Hepatitis B, C & D viral markers in multitransfused thalassemic children: long-term complications and present management |
| Q74751759 | Hepatitis C |
| Q42988161 | Hepatitis C Viral RNA Status at Two Weeks of Therapy Predicts the Eventual Response |
| Q43047908 | Hepatitis C infection in children and adolescents on haemodialysis and after renal transplant |
| Q43048687 | Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. |
| Q43036592 | Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders |
| Q42993177 | Hepatitis C viral load, genotype and histological severity in patients with bleeding disorders |
| Q43040128 | Hepatitis C virus RNA in plasma and blood mononuclear cells in patients with chronic hepatitis C treated with alpha-interferon |
| Q43036983 | Hepatitis C virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects. |
| Q43042104 | Hepatitis C virus after interferon treatment has the variation in the hypervariable region of envelope 2 gene |
| Q42983198 | Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification |
| Q30471164 | Hepatitis C virus in body fluids after liver transplantation |
| Q41398433 | Hepatitis C virus infection in dialysis and renal transplantation |
| Q34370414 | Hepatitis C virus infection in pediatric patients |
| Q41225114 | Hepatitis C virus infection: clinical aspects and treatment with interferon alfa |
| Q43035754 | Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis. |
| Q43049318 | Hepatitis C virus replication in liver and peripheral blood mononuclear cells of interferon-alpha-treated and untreated patients with chronic hepatitis C. |
| Q41123443 | Hepatitis C virus: models of immunopathogenesis and prophylaxis |
| Q71702111 | Hepatitis C: diagnosis and treatment |
| Q36642065 | Hepatitis C: progress and problems |
| Q43041988 | Hepatitis delta virus RNA in serum of patients with chronic delta hepatitis |
| Q42994292 | High rate of chronicity in HCV infection determined by antibody confirmatory assay and PCR in 4110 patients during long-term follow-up |
| Q43035582 | Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study |
| Q43048062 | Horizontal transmission of hepatitis C virus in households of infected children |
| Q42992185 | How soon can a virological sustained response be determined after withdrawal of interferon therapy in chronic hepatitis C? Tokyo-Chiba Hepatitis Research Group |
| Q40612869 | Human immunodeficiency virus and hepatitis--implications for operating room personnel |
| Q92856183 | Humanized Mouse Models for the Study of Hepatitis C and Host Interactions |
| Q43037829 | Idiopathic CD4+ T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. Multicenter Hemophilia Cohort Study |
| Q40371427 | Immune-mediated liver damage in chronic hepatitis C. |
| Q40859833 | Importance of the polymerase chain reaction in the study of hepatitis C virus infection |
| Q34375826 | Initial results with recombinant interferon alfa-2b in patients with chronic hepatitis C: the United States experience |
| Q50587480 | Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial |
| Q30425525 | Interferon therapy for chronic hepatitis C. |
| Q43038369 | Interferon therapy in chronic hepatitis C virus: evidence of different outcome with respect to different viral strains. |
| Q43048088 | Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance schedule in responder patients |
| Q43038924 | Interferon treatment of hepatitis C: Is it virological cure? |
| Q42995643 | Interferon treatment of two patients with quadruple infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), hepatitis G virus (HGV), and TT virus (TTV). |
| Q54096509 | Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade |
| Q72316271 | Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response |
| Q43041374 | Interferon-alpha therapy for hepatitis C virus infection after liver transplantation |
| Q72400571 | Intrahepatic mononuclear cell populations and MHC antigen expression in patients with chronic hepatitis C [correction of B]: effect of interferon-alpha |
| Q42995529 | Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators |
| Q41351271 | Laboratory diagnosis of hepatitis C. |
| Q42995392 | Lack of hepatitis C virus replication intermediate RNA in diseased skin tissue of chronic hepatitis C patients |
| Q42982414 | Limited benefits of INF-alpha therapy in renal graft candidates with chronic viral hepatitis B or C. |
| Q39572121 | Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. |
| Q42996535 | Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years |
| Q43046502 | Long-term biochemical and virological response to natural interferon-alpha in patients with chronic hepatitis C. |
| Q43048890 | Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. |
| Q43039079 | Long-term cohort study of chronic hepatitis C according to interferon efficacy |
| Q73562590 | Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis |
| Q42993893 | Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon |
| Q43039547 | Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α2b |
| Q42981340 | Long-term follow-up of patients with chronic hepatitis C treated with α-interferon |
| Q43041884 | Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response |
| Q36769099 | Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy |
| Q43049420 | Longitudinal study of hepatitis C viremia in chronic hepatitis C. |
| Q34409615 | Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial |
| Q58622883 | Management of hepatitis C |
| Q34422694 | Management of interferon therapy nonresponders |
| Q34521747 | Mechanisms of action of ribavirin in antiviral therapies |
| Q43038003 | Molecular and serologic analysis in the transmission of the GB hepatitis agents |
| Q40524352 | Molecular detection of hepatitis C virus: impact of detection methodology on clinical and laboratory correlations |
| Q71811848 | Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon |
| Q43048166 | Other approaches to the treatment of chronic viral hepatitis |
| Q42991466 | Prediction of efficacy of interferon treatment of chronic hepatitis C and occurrence of HCC after interferon treatment by a new classification |
| Q50888405 | Prediction of efficacy of interferon treatment of chronic hepatitis C by multivariate analysis and a new classification |
| Q42996606 | Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy |
| Q43041709 | Prediction of response to interferon treatment of chronic hepatitis C. |
| Q43041718 | Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon |
| Q34377809 | Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. |
| Q35938868 | Predictive factors for beneficial response to interferon-alfa therapy in chronic hepatitis C. |
| Q45755300 | Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferon |
| Q42552575 | Prolonged therapy of chronic hepatitis C with ribavirin |
| Q42984186 | Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial |
| Q42993182 | Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. |
| Q77470554 | Pruritus as a presenting symptom of chronic hepatitis C |
| Q39654836 | Quantitation of hepatitis C viral RNA in liver and serum samples using competitive polymerase chain reaction |
| Q42987892 | Quantitation of hepatitis C virus in liver and peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection |
| Q45211512 | Quantitative DNA analysis of low-level hepatitis B viremia in two patients with serologically negative chronic hepatitis B. |
| Q42984886 | Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon |
| Q42982877 | Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon |
| Q40931423 | Real-time monitoring of HCV-RNA by single tube assay kit and potential importance for predicting virological sustained response in patients with chronic hepatitis C. |
| Q43039147 | Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non‐A, non‐B hepatitis patients |
| Q40820014 | Recurrent and new hepatitis C virus infection after liver transplantation |
| Q42979741 | Relationship between pretreatment viremia level and response to interferon-alpha therapy in chronic hepatitis C differs in viral type 1 and 2 infections |
| Q34375833 | Results of long term interferon treatment in non A non B/C chronic active hepatitis. The French Group for the study of NANB/C chronic hepatitis treatment |
| Q43041740 | Review: molecular biology of the hepatitis C virus |
| Q43049218 | Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon |
| Q42980410 | Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study |
| Q30304669 | Robotic automation performs a nested RT-PCR analysis for HCV without introducing sample contamination |
| Q44746130 | Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection |
| Q45733166 | SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. |
| Q40847351 | Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial |
| Q43040510 | Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy |
| Q43049077 | Serum ALT: tarnished gold standard for interferon response in hepatitis C virus infection |
| Q42979838 | Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. The Trent HCV Study Group |
| Q43048333 | Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment |
| Q42993889 | Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype |
| Q43041553 | Serum hepatitis C virus RNA levels in chronic hepatitis C--importance for outcome of interferon alfa-2b treatment |
| Q73494360 | Sexual Behavior and Injection Drug Use During Pregnancy and Vertical Transmission of HIV-1 |
| Q43048414 | Short and long-term effects of interferon on serum markers of hepatitis C virus replication |
| Q73019813 | Short-term versus sustained response to interferon therapy: effect on histology |
| Q43036405 | Significance of IgG and IgM HCV antibody secretion in vitro in patients with chronic hepatitis C: correlation with disease activity and response to interferon-alpha |
| Q42984182 | Significance of IgM anti-HCVcore level in chronic hepatitis C |
| Q41836952 | Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C |
| Q42995243 | Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: analysis of HCV RNA in 320 patients who were followed for more than 3 years |
| Q43038048 | Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. |
| Q73629646 | Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy |
| Q42999638 | Tailoring antiviral therapy in hepatitis C. |
| Q43000130 | Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study |
| Q73429693 | The Effect Of Long Term and High Dose Interferon Treatment In Chronic Hepatitis C |
| Q38053544 | The Importance of Rapid Viral Suppression in the Era of Directly Acting Antiviral Therapy for Hepatitis C Virus |
| Q74323439 | The Target Cells of Injected Type I Interferons in Mouse Liver |
| Q42981599 | The association of serum hepatitis C virus RNA with serum aminotransferase activities |
| Q54133163 | The clinical utility of viral quantitation using molecular methods |
| Q42981826 | The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. |
| Q73483382 | The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis |
| Q42996800 | The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. |
| Q40957762 | The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review |
| Q35743655 | The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C. |
| Q42979832 | The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha |
| Q41109684 | Therapy of chronic viral hepatitis |
| Q43982980 | Therapy of hepatitis C |
| Q45761272 | Time course of histological changes in patients with a sustained biochemical and virological response to interferon-α therapy for chronic hepatitis C virus infection |
| Q43001692 | Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response |
| Q58803510 | Transfusion-associated chronic hepatitis C: Alpha-n1 interferon for 6 vs. 12 months |
| Q42981961 | Treatment of children with chronic hepatitis C with recombinant interferon-alpha: a pilot study |
| Q43037270 | Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha |
| Q43047953 | Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients |
| Q42979897 | Treatment with recombinant interferon-alpha 2a for patients with chronic hepatitis C: predictive factors for biochemical and virologic response. Osaka Liver Disease Study Group |
| Q43047084 | Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices |
| Q43036129 | Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma |
| Q35172760 | Viruses, chemotherapy and immunity |
| Q72749710 | [Hepatitis C] |
Search more.